On 3 December 2025, the European Commission adopted the RESourceEU Action Plan, signaling that Europe’s industrial competitiveness will increasingly depend on its ability to secure and diversify critical raw material (“CRM”) supply chains.  For companies, inside and outside the EU, RESourceEU is more than a technical update: it marks a policy shift toward a more interventionist and security-driven approach to CRM governance.

The analysis below outlines the drivers behind the initiative, its main components, and the implications for multinationals trading into the EU.

Continue Reading RESourceEU Action Plan – Strengthening the EU’s Access to Critical Raw Materials

Since our mid-year recap on minors’ privacy legislation, several significant developments have emerged in the latter half of 2025. We recap the notable developments below.

Continue Reading End-of-Year 2025 State and Federal Developments in Minors’ Privacy

At just after 5 am on 11 December 2025, the EU Parliament and the Council reached agreement on a new directive and a new regulation that will result in a major update to the EU’s pharmaceutical laws.  Progress towards these new rules began in 2016 and are the result of…

Continue Reading EU Announces Political Agreement on Pharma Law Review

On December 11, President Trump signed an Executive Order on “Ensuring a National Policy Framework for Artificial Intelligence” (“AI Preemption EO”), the culmination of months of efforts by Republican lawmakers to assert federal primacy over AI regulation.  The AI Preemption EO, which follows the release of a draft version in…

Continue Reading President Trump Signs Executive Order to Block State AI Laws

On December 1, the Washington State AI Task Force (“Task Force”) released its Interim Report with AI policy recommendations to the Governor and legislature. Established by the legislature in 2024, the Task Force is responsible for evaluating current and potential uses of AI in Washington and recommending regulatory and legislative…

Continue Reading Washington State AI Task Force Releases AI Policy Recommendations for 2026

Since the landmark Citizens United decision in 2010, super PACs have become a fixture of U.S. political campaigns. But despite the initial anticipated boom in corporate influence in elections, most super PAC funding to date has come from wealthy individuals, closely-held corporations, and nonprofits, not from large for-profit corporations.

However…

Continue Reading Corporate and Industry “Mega PACs”: The Next Frontier for Super PACs

Many fields of finance involve complex optimization problems under strict time constraints — problems where even marginal improvements could generate immense value for firms. Could quantum computing bring such improvements? Two recent IBM studies with major financial industry participants have explored potential use cases for quantum computing in finance.

Continue Reading Quantum Computing: Quantum Applications in Finance

In the 2024 election cycle, super PACs spent a reported $2.7 billion at the federal level, up from roughly $1.4 billion in 2022. And in 2025, super PACs poured tens of millions into state and local races, including the New Jersey gubernatorial race and the New York City mayoral…

Continue Reading Forming and Operating Super PACs: A Practical Guide for Political Consultants in 2026

On September 24, 2025, Covington’s tech industry experts explored what legal teams, government affairs professionals, and business leaders at tech companies need to know during this pivotal period and offered insights into anticipated challenges and emerging opportunities in the year ahead. Eight Covington attorneys shared their insights during a 60-minute session moderated by Covington partner Holly Fechner. Key takeaways from the Forum are outlined below.

Continue Reading Covington Tech Briefing Spotlight: Impact of Latest Policy Developments on the Tech Industry

On 1 December 2025, the UK Government announced a “landmark” UK-US pharmaceutical deal.   Under the deal, the UK claims to be (so far) the only country to secure zero-percent tariffs on pharmaceuticals exported to the US for the next three years.  In return, the UK has committed to increase its spending on medicines and revise some of the most controversial aspects of the UK pricing and reimbursement system.

Although details as to the implementation of the deal are still unclear, it is clear this will involve major changes to the landscape for commercializing innovator drugs in the UK, after months of attritional and sometimes fractious wrangling between the industry and UK Government.

Continue Reading Landmark UK-US Pharmaceutical Deal